Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents

Trial Profile

Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jan 2008

At a glance

  • Drugs Atorvastatin; Torcetrapib
  • Indications Coronary arteriosclerosis
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms ILLUSTRATE
  • Most Recent Events

    • 16 Jan 2008 The expected completion date for this trial is now 1 Sep 2006.
    • 28 Mar 2007 Results have been reported.
    • 11 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top